中創新航(03931.HK)將H股尚未使用募集資金用於永久補充流動資金
格隆匯12月6日丨中創新航(03931.HK)公吿,董事會謹此宣佈,董事會於2024年12月6日舉行董事會會議。於該會議上,董事會審議並通過(其中包括)關於將H股尚未使用募集資金用於永久補充流動資金的議案。
公司根據市場需求變化,調整產能結構,更好的提升募集資金使用效率考慮,擬將用於四川眉山項目的募集資金529.96百萬港元更改為補充流動資金,其預期將於2025年12月31日前使用完畢。除上述建議變更外,公司全球發售所得款項淨額用途概無其他變動。上述建議變更在進一步提升募集資金利用效率的同時,將進一步增強公司的營運能力,符合公司發展規劃及長遠利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.